#RT @pozmagazine: RT @LizHighleyman: People with #HIV who struggle with adherence achieved viral suppression rates comparable to those in clinical trials when they started long-acting injectable cabotegravir & rilpivirine (@ViiVHC‘s Cabenuva), @MonicaGan… https://t.co/OGE526ZoNi
— Aware Foundation Group (@awarefndngroup) February 23, 2023
Discovered on: 2023-02-23 20:00:56
Source: @awarefndngroup: #RT @pozmagazine: RT @LizHighleyman: People with #HIV who …